A team of US researchers have discovered three antibodies that could enable the development of treatments and vaccines for influenza (flu) virus.

The team involved scientists from Washington University School of Medicine in St Louis, Scripps Research and Icahn School of Medicine at Mount Sinai in New York City. The National Institute of Allergy and Infectious Diseases (NIAID) supported the research.

During the research, the team isolated monoclonal antibodies five days after the onset of symptoms in a person infected with H3N2 flu.

The researchers tested 45 monoclonal antibodies, finding three that bound to neuraminidase (NA) proteins present on the surface of an H3N2 virus strain.

Further testing showed that the three antibodies also bound to NA proteins on several other influenza virus types.

NA proteins are required for virus replication, freeing newly formed viruses from infected cells and allowing them to infect new cells.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

When tested in mice administered with a lethal dose of the flu virus, all three antibodies were observed to be effective against multiple strains. One of the antibodies, 1G01, was effective against all 12 strains tested.

The findings are expected to enable a universal vaccine and a drug to treat severe flu cases. Currently, the team is working to develop vaccines and treatments that could offer long-lasting immunity.

Washington University pathology and immunology assistant professor Ali Ellebedy said: “Neuraminidase has been ignored as a vaccine candidate for a long time. These antibodies tell us that it should not have been overlooked.

“Now that we know what a broadly protective antibody to neuraminidase looks like, we now have an alternative approach to start designing novel vaccines that induce antibodies like this. And that could be really important if we are going to figure out how to design a truly universal vaccine.”